Effect of paroxetine treatment on glycaemic control and quality of life in mildly depressed type two diabetic subjects: a double-blind randomised placebo controlled six month trial
| ISRCTN | ISRCTN55819922 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN55819922 |
| Protocol serial number | N/A |
| Sponsor | GlaxoSmithKline (Finland) |
| Funder | Funded by GlaxoSmithKline |
- Submission date
- 02/08/2006
- Registration date
- 13/09/2006
- Last edited
- 26/06/2007
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Kristian Wahlbeck
Scientific
Scientific
Psychiatric unit
Vaasa Central Hospital
Vaasa
FIN-65130
Finland
| kristian.wahlbeck@stakes.fi |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised double-blind placebo-controlled trial |
| Secondary study design | Randomised controlled trial |
| Scientific title | |
| Study objectives | We hypothesised that paroxetine will have a beneficial effect on quality of life and on glycaemic control in mildly depressed diabetics. |
| Ethics approval(s) | Helsinki University Central Hospital ethics review committee has approved the study in 2001 |
| Health condition(s) or problem(s) studied | Type two diabetes mellitus and depression. |
| Intervention | Paroxetin 20 mg per day or placebo for six months. Blood samples and clinical examination four times during the trial. |
| Intervention type | Drug |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | Paroxetine |
| Primary outcome measure(s) |
10% decrease in HbA1c. |
| Key secondary outcome measure(s) |
20% improvement in quality of life as defined by the RAND-36 health relate quality of life questionnaire. |
| Completion date | 20/12/2002 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | All |
| Target sample size at registration | 38 |
| Key inclusion criteria | 1. Volunteers between 50 and 70 years of age 2. Diagnosed type two diabetes 3. Hba1c more than 7.0% 4. Mild symptoms of depression |
| Key exclusion criteria | 1. Moderate to severe depression based on Diagnostic and Statistical Manual of mental disorders (DSM-IV) criteria 2. Severe diabetic complications 3. Use of warfarin 4. Glaucoma |
| Date of first enrolment | 01/06/2001 |
| Date of final enrolment | 20/12/2002 |
Locations
Countries of recruitment
- Finland
Study participating centre
Psychiatric unit
Vaasa
FIN-65130
Finland
FIN-65130
Finland
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | Results: | 15/06/2007 | Yes | No |